Jackson Immunoresearch Europe Limited 05155990 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is the sale of specialist research products. Digita Accounts Production Advanced 6.30.9574.0 true true false 05155990 2023-01-01 2023-12-31 05155990 2023-12-31 05155990 bus:OrdinaryShareClass1 2023-12-31 05155990 bus:OrdinaryShareClass2 2023-12-31 05155990 core:CurrentFinancialInstruments 2023-12-31 05155990 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 05155990 core:FurnitureFittings 2023-12-31 05155990 bus:SmallEntities 2023-01-01 2023-12-31 05155990 bus:Audited 2023-01-01 2023-12-31 05155990 bus:FilletedAccounts 2023-01-01 2023-12-31 05155990 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 05155990 bus:RegisteredOffice 2023-01-01 2023-12-31 05155990 bus:Director10 2023-01-01 2023-12-31 05155990 bus:Director2 2023-01-01 2023-12-31 05155990 bus:Director3 2023-01-01 2023-12-31 05155990 bus:Director4 2023-01-01 2023-12-31 05155990 bus:Director5 2023-01-01 2023-12-31 05155990 bus:Director8 2023-01-01 2023-12-31 05155990 bus:Director9 2023-01-01 2023-12-31 05155990 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 05155990 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 05155990 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 05155990 core:FurnitureFittings 2023-01-01 2023-12-31 05155990 core:ParentEntities 2023-01-01 2023-12-31 05155990 1 2023-01-01 2023-12-31 05155990 countries:EnglandWales 2023-01-01 2023-12-31 05155990 2022-12-31 05155990 core:FurnitureFittings 2022-12-31 05155990 2022-01-01 2022-12-31 05155990 2022-12-31 05155990 bus:OrdinaryShareClass1 2022-12-31 05155990 bus:OrdinaryShareClass2 2022-12-31 05155990 core:CurrentFinancialInstruments 2022-12-31 05155990 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 05155990

Jackson Immunoresearch Europe Limited

Filleted Abridged Financial Statements

for the Year Ended 31 December 2023

 

Jackson Immunoresearch Europe Limited

Contents

Company Information

1

Abridged Balance Sheet

2

Notes to the Abridged Financial Statements

3 to 9

 

Jackson Immunoresearch Europe Limited

Company Information

Directors

Mrs Susan Caroline Hallett

Mr Leonard Charles Giunta

Mr Ian James Nicholls

Mr Matthew Stephen Smith

Mr Ralph C Hood JR

Mr David Ashley Fancy

Mrs Tiffany Nicole Mcpeak

Registered office

Cambridge House
St Thomas' Place
Cambridgeshire Business Park
Ely
CB7 4EX

Auditors

Tayabali & White
5 High Green
Great Shelford
Cambridge
Cambridgeshire
CB22 5EG

 

Jackson Immunoresearch Europe Limited

(Registration number: 05155990)
Abridged Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Current assets

 

Stocks

5

51,616

85,777

Debtors

6

1,005,834

515,570

Cash at bank and in hand

 

1,192,835

1,473,470

 

2,250,285

2,074,817

Prepayments and accrued income

 

26,675

27,533

Creditors: Amounts falling due within one year

(950,083)

(903,544)

Total assets less current liabilities

 

1,326,877

1,198,806

Accruals and deferred income

 

(10,728)

(7,000)

Net assets

 

1,316,149

1,191,806

Capital and reserves

 

Called up share capital

7

160

160

Retained earnings

1,315,989

1,191,646

Shareholders' funds

 

1,316,149

1,191,806

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 20 June 2024 and signed on its behalf by:
 

.........................................
Mr Ian James Nicholls
Director

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Cambridge House
St Thomas' Place
Cambridgeshire Business Park
Ely
CB7 4EX

These financial statements were authorised for issue by the Board on 20 June 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The presentation currency is £ sterling.

Going concern

The financial statements have been prepared on a going concern basis.

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

Audit report

The Independent Auditor's Report was unqualified. . The name of the Senior Statutory Auditor who signed the audit report on 1 August 2024 was Simon White BA(Hons) FCA, who signed for and on behalf of Tayabali & White.

.........................................

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

25% on reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks have been valued at the lower of cost and estimated selling price less costs to complete and sell.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Recognition and measurement
The company accounts for gains and losses on forward currency by translating the value at the forward rate on the Balance Sheet date compared to the contracted rate at completion.
 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 8 (2022 - 9).

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

4

Tangible assets

Fixtures and fittings
£

Total
£

Cost or valuation

At 1 January 2023

18,710

18,710

At 31 December 2023

18,710

18,710

Depreciation

At 1 January 2023

18,710

18,710

At 31 December 2023

18,710

18,710

Carrying amount

At 31 December 2023

-

-

5

Stocks

2023
£

2022
£

Finished goods and goods for resale

51,616

85,777

6

Debtors

Debtors includes £Nil (2022 - £Nil) due after more than one year.

7

Share capital

Allotted, called up and fully paid shares

2023

2022

No.

£

No.

£

Ordinary A £1 of £1 each

60

60

60

60

Ordinary B £1 of £1 each

100

100

100

100

160

160

160

160

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

8

Dividends

2023

2022

£

£

Final dividend of £100,000.00 (2022 - £200,000.00) per ordinary share

100,000

200,000

Interim dividend of £720,000.00 (2022 - £720,000.00) per ordinary share

720,000

720,000

820,000

920,000

 

 

9

Related party transactions

 

Jackson Immunoresearch Europe Limited

Notes to the Abridged Financial Statements for the Year Ended 31 December 2023

Directors' remuneration

The directors' remuneration for the year was as follows:

2023
£

2022
£

Remuneration

91,611

37,660

Contributions paid to money purchase schemes

4,654

1,920

96,265

39,580

Summary of transactions with parent

Jackson ImmunoResearch Laboratories Inc
Parent company
872 West Baltimore Pike,
West Grove,
PA 19390

No group accounts are prepared.

 During the year, the company incurred purchases and other expenses of £4,238,685 (2022 £3,984,369) from the parent company. The amount owing to the parent company at the balance sheet date was £697,662 (2022 £709,243).

In addition, the company recovered marketing expenses, including wages, of £214,167 (2022 £211,933) on behalf of the parent company. These amounts were recharged in the year and the balance owing from the parent company at the year end was £161,586 (2022 £94,374).

The transactions were carried out at normal commercial rates.

No amounts were written off during the year.

 

10

Parent and ultimate parent undertaking

The company's immediate parent is Jackson ImmunoResearch Laboratories Inc, incorporated in USA.

 The ultimate controlling party is no single ultimate controlling entity.